Overview
Liver Function Tests are a group of blood investigations that provide indirect information about liver health. The liver plays a vital role in the metabolism of carbohydrates, proteins, and lipids, the synthesis of albumin and clotting factors, the detoxification of drugs and toxins, the storage of glycogen and vitamins, and the excretion of bilirubin and cholesterol through bile.
LFTs do not measure all liver functions directly but assess enzymes, proteins, and waste products that offer clues about the type and pattern of liver injury. The panel commonly includes ALT, AST, ALP, GGT, bilirubin, albumin, and PT/INR. These markers help differentiate hepatocellular injury, cholestasis, and synthetic dysfunction.
Symptoms
LFTs are indicated in patients with jaundice, abdominal pain, or suspected liver disease. They are used for screening potential liver infections, monitoring toxic medication effects, evaluating heavy or chronic alcohol use, and assessing the progression of known liver disease, such as cirrhosis. Elevated liver enzymes may be detected incidentally in asymptomatic individuals.
Abnormal values can also present in cases of biliary obstruction, gallstones, or hepatic scarring. Severe liver dysfunction may lead to hepatic coma, where rising ammonia levels correlate with increasing neurological symptoms such as confusion, irritability, somnolence, and deep coma.
Causes
Abnormal LFT patterns reflect different underlying mechanisms. Hepatocellular injury typically shows marked elevation of ALT and AST, often more than ten to twenty times the upper limit of normal.
ALT is more liver-specific, while AST may also rise in muscle injury or myocardial infarction. An AST to ALT ratio greater than two suggests alcoholic liver disease. Cholestatic patterns show elevated ALP and GGT, indicating biliary obstruction or primary biliary disease. Increased bilirubin may indicate liver dysfunction, hemolysis, or biliary blockage.
Synthetic failure is reflected by low albumin and prolonged PT/INR, indicating impaired protein production and clotting factor synthesis. Asymptomatic enzyme elevation may occur due to medications such as statins or NSAIDs, alcohol use, metabolic conditions like nonalcoholic fatty liver disease and diabetes, muscle injury, viral carriers, or other systemic diseases.
Extrahepatic causes must also be considered, including myopathy, bone disease, hemolysis, chronic kidney disease, heart failure, nephrotic syndrome, and malnutrition.
Risk Factors
Chronic alcohol consumption increases the risk of hepatocellular damage and abnormal AST to ALT ratios. Viral infections such as hepatitis contribute to elevated transaminases.
Metabolic disorders, including fatty liver disease and diabetes, predispose to abnormal enzyme levels. Use of hepatotoxic medications increases the likelihood of liver injury. Chronic biliary obstruction or gallstones raise ALP and GGT levels. Severe liver disease may progress to cirrhosis and hepatic coma.
Patients with heavy alcohol intake, chronic infections, metabolic syndrome, or long-term medication use are at higher risk of abnormal LFT findings.
Prevention
Early detection through screening and appropriate monitoring reduces the risk of severe liver complications. Monitoring medication side effects helps prevent drug-induced liver injury. Addressing alcohol misuse lowers the risk of hepatocellular damage. Managing metabolic conditions such as fatty liver disease and diabetes supports liver health.
Timely investigation of jaundice and abnormal results allows early identification of viral hepatitis, biliary obstruction, or cirrhosis. Proper interpretation of LFT patterns in the clinical context is essential, as normal values do not always guarantee a healthy liver, and enzyme levels may not directly correlate with disease severity.
Comprehensive evaluation, including history, examination, and further diagnostic testing, ensures accurate diagnosis and effective management of liver disorders.
